Chemical Structure and Pharmacology | Pharmacokinetics | Adverse Effects Profile | Efficacy
Escitalopram is the active (S)-enantiomer of citalopram, which
has been shown to be twice as potent as citalopram with respect
to serotonin inhibition (Aronson and Delgado 2004).
With oral administration of 10 mg, it is rapidly and almost entirely
absorbed, and achieves peak plasma concentrations of 10–30
ng/mL in approximately 2–6 hours (Table
(Rao 2007). Its affinity for dopamine and norepinephrine
receptors is negligible. Like citalopram, escitalopram inhibits
serotonin reuptake. Radioligand single-photon emission computed
tomography (SPECT) studies with patients receiving escitalopram
or citalopram indicate that serotonin transporter occupancy in the
midbrain was higher with escitalopram (N. Klein et al. 2007).